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Klebsiella spp. are among the most frequently isolated bacteria from burn
wounds. These organisms are among the most important opportunistic pathogens,
causing hospital-acquired and healthcare-associated infections worldwide. Limited
information is available about prevalence of AmpC-producing Klebsiella pneumoniae
from burn patients. Therefore, the aim of this study was to determine the characteri-
zation of AmpC beta-lactamase among K. pneumoniae isolated from burn patients.
Samples were collected from wound specimens of patients with burn injury from a
burn hospital in Tehran during 18 months (March 2015 to August 2016). For
phenotypic detection of AmpC beta-lactamase, disk diffusion method with cefoxitin
was used for screening, AmpC disk test and boronic acid inhibitor-based method were
used as conﬁrmatory tests. Polymerase chain reaction (PCR) was performed to screen
all isolates with AmpC genes including ACCM, DHAM, EBCM, FOXM, MOXM,
and CITM. Finally, PCR products were validated using sequencing. During this study,
102 isolates of K. pneumoniae were collected. Among these isolates, 52.9% suspected
as AmpC producer by disk agar diffusion cefoxitin screening method. By conﬁrmatory
phenotypic methods, 19.6% of isolates considered as AmpC producer. Molecular
analysis revealed 43.1% of cefoxitin-resistant isolates harbored at least one of the
AmpC genes including CITM (22.5%), EBCM (21.5%), DHAM (7.8%), and FOXM
(0.98%). In addition, 5.8% of isolates harbored two AmpC genes and 2.9% harbored
three AmpC genes. In conclusion, K. pneumoniae is becoming a serious problem in
burn patients. Accurate and precise methods and guidelines should be designed for
detection of antibiotic-resistant mechanisms. Our data showed the high rate of AmpC
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beta-lactamase among K. pneumoniae isolated from burn patients, which limit the
treatment options. Therefore, the results of this study can provide evidence to help for
appropriate treatment of burn patients.
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Introduction
In comparison with different type of nosocomial infections among hospi-
talized patients, burn patients are more susceptible to nosocomial infections
because of their immunocompromised state. In this situation, antibacterial treat-
ments of these patients are important in burn wards. For example, choosing the
best antibiotic regimens is a crucial means of infections prevention and control.
Unfortunately, during recent decades the widespread use of antibiotics led to the
emergence of drug-resistant bacteria, such as multidrug and extensively drug-
resistant organisms. Thus in that area, precise knowledge of the bacterial resistance
patterns is essential for determining the best antibiotic regimens or empirical
therapy in critical conditions, for treatment of burn patients [1].
Klebsiella spp. are among the most frequently isolated bacteria from burning
wounds [2]. This organism is one of the most important opportunistic pathogens,
causing hospital-acquired and healthcare-associated infections worldwide [3]. In
recent decades, due to its tendency to develop antibiotic resistance and increasing
virulence factor, lead to emerging this bacterium as clinically important organism
[4, 5]. Klebsiella pneumoniae strains commonly have different types of
beta-lactamase enzymes such as extended-spectrum beta-lactamases (ESBLs),
AmpC beta-lactamases, and carbapenemases, which confer resistance to different
types of beta-lactam antibiotics [6]. The AmpC beta-lactamases are particularly
troublesome group because can easily be transmitted by conjugation to other
bacteria, which has increased incidence worldwide [7]. According to the Ambler
classiﬁcation, AmpCs belong to Class C beta-lactamase. AmpC genes may be
located on chromosome or plasmids. In addition to resistance to penicillins and
most cephalosporins, unlike ESBLs, AmpC-producing organisms can degrade
cephamycins [8]. AmpC beta-lactamase-producing organisms show more exten-
sive antibiotic resistance features in comparison with other ESBLs-producing
organisms [9]. It has been reported that AmpC beta-lactamase can confer resistance
to cefepime (fourth-generation cephalosporin antibiotic) and also can increase the
minimum inhibitory concentration (MIC) value of carbapenems [9, 10].
With respect to clinically important AmpC-producing strains, standard
guidelines do not introduce the ideal test for AmpC detection. However, poly-
merase chain reaction (PCR) remains the gold standard for the detection of AmpC
beta-lactamases [11].
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Thus, due to the lack of standard guiding principle for the revealing of
AmpC, little is known about the prevalence of AmpC-producing K. pneumoniae
among burn patients, which early detection and identiﬁcation of AmpC lead to
implementation of the ideal antimicrobial therapy, and also may allow infectious
control measures to be introduced to prevent spread of drug-resistant organisms.
Therefore, the aim of this study was to determine the characterization of AmpC




This study was a cross-sectional study. Samples were collected from wound
specimens of patients with burn injury from a burn hospital in Tehran, Iran during
18 months (March 2015 to August 2016). Phenotypic identiﬁcation and bio-
chemical validations performed for K. pneumoniae detection according to medical
laboratory guidelines.
Phenotypic detection of AmpC beta-lactamase
For screening of AmpC beta-lactamase disk diffusion method with cefox-
itin, amoxicillin–clavulanate, cefotaxime, and ceftazidime antibiotic disks was
performed according to the guidelines of Clinical and Laboratory Standards
Institute [12]. The isolates, which were resistant to all of the disks considered
as AmpC producer. Then conﬁrmatory tests, such as AmpC disk test, boronic acid
inhibitor-based method were performed [13, 14]. K. pneumoniae ATCC 700603
was used as standard strain.
Molecular analysis of AmpC
For molecular evaluation, the boiling method was used for extracting DNA.
PCR was performed to screen all isolates with AmpC genes including ACCM,
DHAM, EBCM, FOXM, MOXM, and CITM. Speciﬁc primers were used for
each gene (Table I) [15]. PCR was performed by thermal cycler (Eppendorf,
Mastercycler gradient). PCR was carried out in a total volume of 25 μl containing
2 mMMgCl2, 1 μl PCR buffer, 2 mM dNTPs, 1 pmol of primers, 0.25 U Taq DNA
polymerase (CinnaGen Co., Iran), and 5 μl of template DNA. PCR products were
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analyzed by electrophoresis on 1% (w/v) agarose gel (Merck, Germany) contain-
ing ethidium bromide and the gels were visualized under UV light irradiation
(Gel DocTM XR+, USA). Finally, PCR products were validated using sequencing
(Bioscience Co., UK).
Results
During this study, 102 isolates of K. pneumoniae were collected from burn
wound infections. Among these isolates, 52.9% (n= 54) suspected as AmpC
producer by disk agar diffusion (DAD) cefoxitin screening method. By conﬁrma-
tory phenotypic methods for detection of AmpC, 19.6% (n= 20) of isolate
considered as AmpC producer (Figure 1).
Molecular analysis revealed 43.1% (n= 44) of isolates harbored at least one
of the AmpC genes including CITM 22.5% (n= 23), EBCM 21.5% (n= 22),
DHAM 7.8% (n= 8), and FOXM 0.98% (n= 1) (Table II). In addition, 5.8%
(n= 6) of isolates harbored two AmpC genes and 2.9% (n= 3) harbored three
AmpC genes (Table III).
Discussion
In this study, the prevalence of AmpC-producing K. pneumoniae isolates
among burn wound infections was evaluated by phenotypic and genotypic
methods. By cefoxitin screening method, 52% of isolates suspected as AmpC






ACCM F-AAC AGC CTC AGC AGC CGG TTA 58.6 346
R-TTC GCC GCA ATC ATC CCT AGC
DHAM F-AAC TTT CAC AGG TGT GCT GGGT 60 405
R-CCG TAC GCA TAC TGG CTT TGC
EBCM F-TCG GTA AAG CCG ATG TTG CGG 63 302
R-CTT CCA CTG CGG CTG CCA GTT
FOXM F-AAC ATG GGG TAT CAG GGA GATG 59 190
R-CAA AGC GCG TAA CCG GAT TGG
MOXM F-GCT GCT CAA GGA GCA CAG GAT 63 520
R-CACATTGAC ATA GGTGTGGTGC
CITM F-TGG CCA GAA CTG ACA GGC AAA 63 426
R-TTT CTC CTG AAC GTG GCT GGC
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producer, but by conﬁrmatory methods just 19% of isolates considered as
AmpC producer. Molecular analysis revealed that 43% of isolates harbor AmpC
beta-lactamase genes. In our analysis, high rate of false negative results was seen
in phenotypic detection methods. But, cefoxitin was more sensitive than pheno-
typic methods. Any AmpC genes were not detected in the ten cefoxitin-resistant
strains. One reason for this phenotypic resistance is due to loss of outer membrane
porins [16].
Figure 1. Compression of different methods for AmpC beta-lactamase detection
Table II. Distribution of AmpC genes among clinical isolates of K. pneumoniae
Distribution of AmpC genes CITM EBCM DHAM FOXM
% of isolates (N) 22.5 (23) 21.5 (22) 7.8 (8) 0.98 (1)
% of isolates among AmpC producer (N) 52.2 (23) 50 (22) 18.1 (8) 2.2 (1)
Table III. Coexistence of AmpC genes among clinical isolates of K. pneumoniae









% of isolates (N) 1.9 (2) 2.9 (3) 0.98 (1) 1.9 (2)
% of isolates among AmpC
producer (N)
4.5 (2) 6.8 (3) 18.1 (8) 4.5 (2)
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Our analysis revealed the high prevalence of AmpC beta-lactamase among
clinical isolates of K. pneumoniae isolated from burn patients. According to Azimi
et al.’s study during 2013 in Iran, the prevalence of AmpC beta-lactamase among
clinical isolates of K. pneumoniae was reported 1.6% [17]. Our data showed the
sharp rise of AmpC beta-lactamase incidence over the past 3 years. Some studies
have showed that AmpC beta-lactamases are produced in upward of 50% of
clinical isolates [18–20]. A limited number of antibiotic treatment options are
available in infections caused by AmpC-producing K. pneumoniae. Carbapenems
have emerged as a primary agent for management of infections due to AmpC-
producing K. pneumoniae [9]. However, it has been reported that AmpC beta-
lactamase can increase the MIC value of carbapenems and confer resistance to this
class of antibiotics [10, 11].
Japoni-Nejad et al. [21] during 2014 in Iran showed that 19% of clinical
isolates of K. pneumoniae harbor AmpC genes. Of this 19%, 42.2% carried CITM
gene, 36.8% carried MOX gene, whereas 15.7% and 5.2% carried EBCM and
DHAM genes, respectively. According to our data, the most AmpC genes
prevalent among the K. pneumoniae isolated from burn infections are CITM and
EBCM, respectively. Our data reveal that shifting the prevalence of AmpC genes
occurred during the short time in our country. In addition, according to Jean et al.’s
[22] study, the most abundant AmpC beta-lactamase variant among clinical
isolates of K. pneumoniae in Asia-Paciﬁc region was DHAM.
In our analysis, eight strains were found which coharbored at least two
AmpC genes. Two of these isolates were coharbored three AmpC genes.
Therefore, this study is the ﬁrst report of coexistence of AmpC genes in clinical
isolates of K. pneumoniae.
In conclusion, K. pneumoniae is becoming a serious problem in burn
patients. Accurate and precise methods and guidelines should be designed for
detection of antibiotic resistance mechanisms. Our data showed high rate of AmpC
beta-lactamase among K. pneumoniae isolated from burn patients, which limit the
treatment options. Therefore, the results of this study provide evidence to help for
appropriate treatment of burn patients. Infection control programs and strict
antimicrobial stewardship policies should be applied to reduce the prevalence of
these high-risk strains. Finally, using the antibacterial activities of medicinal plants
with low level of toxicity can improve treatment of infection due to drug-resistant
organisms [23, 24].
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